Skip to main content

Table 4 Cox model of association of baseline characteristics with overall survival

From: Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program

Characteristic

Univariate analysis

Multivariate analysis

HR (95% CI)

P value

HR (95% CI)

P value

Age, years

  ≥ 75 vs < 75

0.62 (0.39–0.98)

0.04

0.55 (0.35–0.87)

0.01

Gender

 Male vs female

1.18 (0.82–1.71)

0.36

–

 

Metastatic site, yes vs no

 Bone

1.35 (0.99–1.84)

0.06

–

 

 Liver

1.05 (0.76–1.46)

0.75

–

 

 CNS

1.39 (0.84–2.31)

0.20

–

 

Number of prior therapies

  > 1 vs 1

1.80 (1.15–2.87)

0.01

–

 

First line

 Sunitinib vs pazopanib

1.24 (0.84–1.84)

0.28

  

Prior everolimus

 Yes vs no

1.30 (0.95–1.76)

0.10

  

Drug-related toxicity (drAEs)

 Yes vs no

0.64 (0.46–0.91)

0.01

–

 

Ir toxicity (irAEs)

 Yes vs no

0.48 (0.30–0.78)

0.003

0.57 (0.35–0.93)

0.02

Number of Nivolumab doses

  > 4 vs ≤4

0.11 (0.08–0.15)

< 0.0001

0.11 (0.08–0.15)

< 0.0001

  1. Abbreviations: CI confidence interval, HR hazard ratio, CNS central nervous system
Back to article page